Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111644 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
NCT00111644: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00111644 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 302 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (127% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111644, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Interventions
- DRUG Ceftriaxone
- DRUG beta-lactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00111644 record still lists
NCT00111644 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (127% higher).
The record links to 0 conditions, and to 2 interventions - of which Ceftriaxone is the first listed.
NCT00111644 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111644 about?
NCT00111644 is a clinical study titled "A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia". This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
What is the current status of trial NCT00111644?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2005-03. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00111644?
The interventions under investigation include: Ceftriaxone (DRUG), beta-lactam (DRUG).
Who is sponsoring clinical trial NCT00111644?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00111644's enrollment target sits among peer trials
302 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia